{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-240991","form_type":"8-K","ticker":"QTTB","cik":"0001661998","company_name":"Q32 Bio Inc.","filed_at":"2022-09-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.575564+00:00","generated_at":"2026-06-23T12:56:38.657358+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Homology Medicines appoints Albert Seymour as CEO; Arthur Tzianabos named Chairman","bullets":["Albert Seymour, former CSO and President, promoted to CEO; base salary raised to $570,000, bonus target 55%.","Seymour received option for 23,000 shares at $2.18 and 14,000 RSUs, vesting over 48 months and 3 years.","Arthur Tzianabos resigned as CEO, appointed Chairman of Board; consulting agreement pays $26,571/month through March 31, 2023.","Kush Parmar resigned from Board and Chairman role; Jeffrey Poulton appointed Lead Director.","CFO W. Bradford Smith's severance amended: 12 months base salary continuation on qualifying termination."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-240991","json":"https://secwatch.observer/filing/0001193125-22-240991.json","markdown":"https://secwatch.observer/filing/0001193125-22-240991.md","text":"https://secwatch.observer/filing/0001193125-22-240991.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661998/000119312522240991/0001193125-22-240991-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661998/000119312522240991/d403635d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T12:56:38.657358+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3622514c7d","claim":"Albert Seymour was appointed as Class II Director at Q32 Bio Inc..","evidence_excerpt":"Also on September 6, 2022, the Board appointed Albert Seymour, Ph.D. as a Class II director of the Company, replacing Kush M. Parmar, M.D., Ph.D., who resigned from his position as a member of the Board and as Chairman of the Board on the same date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661998/000119312522240991/0001193125-22-240991-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"},{"claim_id":"44e861100a","claim":"Jeffrey V. Poulton was appointed as Lead Director at Q32 Bio Inc..","evidence_excerpt":"and has also appointed Jeffrey V. Poulton to serve as the Lead Director of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661998/000119312522240991/0001193125-22-240991-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Lead Director"}],"fact_type":"executive_change"},{"claim_id":"6738772343","claim":"Arthur O. Tzianabos was appointed as Chairman of the Board at Q32 Bio Inc..","evidence_excerpt":"The Board has appointed Arthur O. Tzianabos, Ph.D. to replace Dr. Parmar as the Chairman of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661998/000119312522240991/0001193125-22-240991-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"},{"claim_id":"6c83117b20","claim":"Arthur O. Tzianabos resigned as Chief Executive Officer at Q32 Bio Inc..","evidence_excerpt":"On September 6, 2022, in connection with Dr. Seymour’s promotion, Dr. Tzianabos notified the Company of his resignation as Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661998/000119312522240991/0001193125-22-240991-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"edb868f40b","claim":"Albert Seymour was appointed as Chief Executive Officer at Q32 Bio Inc..","evidence_excerpt":"On September 6, 2022, the Board of Directors (the “ Board ”) of Homology Medicines, Inc. (the “ Company ”) appointed Albert Seymour, Ph.D., the Company’s former Chief Scientific Officer and President, to serve as the Company’s Chief Executive Officer, in addition to his role as the Company’s President.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661998/000119312522240991/0001193125-22-240991-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"ee5731a01c","claim":"Kush M. Parmar resigned as Chairman of the Board at Q32 Bio Inc..","evidence_excerpt":"Also on September 6, 2022, the Board appointed Albert Seymour, Ph.D. as a Class II director of the Company, replacing Kush M. Parmar, M.D., Ph.D., who resigned from his position as a member of the Board and as Chairman of the Board on the same date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661998/000119312522240991/0001193125-22-240991-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}